Novo Nordisk doubles stock of Wegovy starter doses but supply constraints persist: CEO

Even with a competitor’s drug now on the scene, Novo Nordisk is aiming for another year of dominance in the obesity arena thanks in large part to a resupply of starter doses of the company’s weight-loss blockbuster Wegovy.